Mapracorat

























It's just another thing research can claim they are working on to help B&L paint a picture that it's trying to "keep the lights on"

All of the money spent on pharmaceutical R+D with no return on the investment is what is turning the lights off at B+L. Can the historical or probability of future success justify the current pharmaceutical R+D management team moving forward?

Maybe some new R+D blood needed in this area.